Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7,486 Mln
Revenue (TTM)
$1,397 Mln
Net Profit (TTM)
$0 Mln
ROE
1.5 %
ROCE
-- %
P/E Ratio
24.7
P/B Ratio
153.4
Industry P/E
--
EV/EBITDA
16.6
Div. Yield
0 %
Debt to Equity
--
Book Value
$0.4
EPS
$2.7
Face value
--
Shares outstanding
118,017,000
CFO
$847.72 Mln
EBITDA
$944.38 Mln
Net Profit
$722.29 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Halozyme Therapeutics (HALO)
| -8.4 | -11.0 | -10.5 | -3.4 | 21.3 | 8.3 | 21.4 |
|
BSE Sensex
| -13.1 | -10.5 | -13.5 | -4.8 | 8.6 | 8.5 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Halozyme Therapeutics (HALO)
| 40.8 | 29.1 | -35.0 | 41.5 | -5.9 | 140.9 | 21.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Halozyme Therapeutics (HALO)
|
61.6 | 7,485.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.7 | 153.4 |
| 57.8 | 7,888.0 | 1,091.0 | 202.3 | 31.6 | 31.3 | 35.2 | 13.9 | |
| 217.0 | 13,621.9 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 62.5 | 7,599.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 41.5 | 11,065.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.8 | 5.0 | |
| 84.6 | 11,173.1 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.4 | 8,708.1 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 510.7 | 10,120.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 451.2 | 12,842.8 | 2,530.2 | 451.1 | 21.3 | 70.2 | 29.6 | 28.5 | |
| 290.1 | 8,308.2 | 0.0 | -303.3 | -- | -45.8 | -- | 9.5 |
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the... patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California. Read more
President, CEO & Director
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
President, CEO & Director
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Halozyme Therapeutics Inc (HALO) is $61.63 (NASDAQ) as of 27-Mar-2026 16:00 EDT. Halozyme Therapeutics Inc (HALO) has given a return of 21.35% in the last 3 years.
The P/E ratio of Halozyme Therapeutics Inc (HALO) is 24.68 times as on 20-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
24.99
|
162.23
|
|
2024
|
13.93
|
17.01
|
|
2023
|
17.20
|
57.79
|
|
2022
|
39.02
|
46.45
|
|
2021
|
14.40
|
29.45
|
The 52-week high and low of Halozyme Therapeutics Inc (HALO) are Rs 82.22 and Rs 47.50 as of 28-Mar-2026.
Halozyme Therapeutics Inc (HALO) has a market capitalisation of $ 7,486 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Halozyme Therapeutics Inc (HALO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.66
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.